Evidence map›Paper›PMID 25325982›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2015

Role of glycosaminoglycans in infectious disease.

Akiko Jinno, Pyong Woo Park

Open access · greenAbstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
6.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 63 citations in OpenAlex.

  1. Review
  2. Article
  3. Effect of Selection for Low and HighPathogens (Basel, Switzerland) · 2025
    Article
  4. Article
  5. Mechanisms ofFrontiers in cellular and infection microbiology · 2025
    Review
  6. Review
  7. TRPA1 InfluencesInternational journal of molecular sciences · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Gastrointestinal biofilms in health and disease.Nature reviews. Gastroenterology & hepatology · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Akiko JinnoDivision of Respiratory Diseases, Children's Hospital, Harvard Medical School, 320 Longwood Avenue, Enders-461, Boston, MA, 02115, USA, akiko.ohno@childrens.harvard.edu.
Pyong Woo Park
Boston Children's Hospital · USHarvard University · US

Funding

HSPGs in Ocular Surface DiseasesR01EY021765 · NEI · BOSTON CHILDREN'S HOSPITAL · PI PARK, PYONG WOO · 2012 to 2016
$1.9M
Syndecan Interactions in Lung Injury and RepairR01HL107472 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI PARK, PYONG WOO · 2011 to 2014
$1.7M
NEI NIH HHS R01 EY021765NHLBI NIH HHS R01 HL107472
6 · The paper itself

Abstract

Glycosaminoglycans (GAGs) have been shown to bind to a wide variety of microbial pathogens, including viruses, bacteria, parasites, and fungi in vitro. GAGs are thought to promote pathogenesis by facilitating pathogen attachment, invasion, or evasion of host defense mechanisms. However, the role of GAGs in infectious disease has not been extensively studied in vivo and therefore their pathophysiological significance and functions are largely unknown. Here we describe methods to directly investigate the role of GAGs in infections in vivo using mouse models of bacterial lung and corneal infection. The overall experimental strategy is to establish the importance and specificity of GAGs, define the essential structural features of GAGs, and identify a biological activity of GAGs that promotes pathogenesis.

Indexed as

Administration, IntranasalAnimalsAntimicrobial Cationic PeptidesCommunicable DiseasesCorneaGlycosaminoglycansHeparan SulfateLungMice, Inbred BALB CMice, KnockoutMicrobial Sensitivity TestsMicrobial ViabilityPseudomonas aeruginosaPseudomonas InfectionsStaphylococcal InfectionsStaphylococcus aureusAntimicrobial Cationic PeptidesGlycosaminoglycansHeparan SulfateSyndecan-1

Identifiers

PMID25325982
PMCPMC4624626
OpenAlexW2197234312

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.